Login to Your Account



Fun With Finances

Slow Start to VC Investments in 2013, Spec Pharma Swells

By Brian Orelli
BioWorld Today Columnist

Monday, April 1, 2013
financings_resized.jpg

Did all the venture capitalists get washed out to sea by Superstorm Sandy? Maybe they all followed in Benedict's footsteps and resigned? Because they sure weren't doing very many deals in the first quarter.

According to BioWorld data for VC funding of U.S. companies developing therapeutics, the number of deals dropped from 25 in the first quarter of last year to 21 this year.

The total value of those deals looked even bleaker, falling 27 percent from $391 billion last year to just $285.5 billion this year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription